These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30990765)

  • 1. Is It Time to Expand the Definition of Washout Appearance in LI-RADS?
    Fowler KJ; Sirlin CB
    Radiology; 2019 Jun; 291(3):658-659. PubMed ID: 30990765
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
    Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
    J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.
    Min JH; Kim JM; Kim YK; Kang TW; Lee SJ; Choi GS; Choi SY; Ahn S
    Hepatology; 2018 Dec; 68(6):2254-2266. PubMed ID: 30070365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
    Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
    AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.
    Ehman EC; Behr SC; Umetsu SE; Fidelman N; Yeh BM; Ferrell LD; Hope TA
    Abdom Radiol (NY); 2016 May; 41(5):963-9. PubMed ID: 27193793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR images following liver imaging reporting and data system (LI-RADS).
    Kim Y; Furlan A; Borhani AA; Bae KT
    J Magn Reson Imaging; 2018 Mar; 47(3):710-722. PubMed ID: 28556283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatobiliary agents and their role in LI-RADS.
    Hope TA; Fowler KJ; Sirlin CB; Costa EA; Yee J; Yeh BM; Heiken JP
    Abdom Imaging; 2015 Mar; 40(3):613-25. PubMed ID: 25287679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability, Validity, and Reader Acceptance of LI-RADS-An In-depth Analysis.
    Barth BK; Donati OF; Fischer MA; Ulbrich EJ; Karlo CA; Becker A; Seifert B; Reiner CS
    Acad Radiol; 2016 Sep; 23(9):1145-53. PubMed ID: 27174029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.
    Joo I; Lee JM; Lee DH; Ahn SJ; Lee ES; Han JK
    J Magn Reson Imaging; 2017 Mar; 45(3):731-740. PubMed ID: 27474328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma.
    Chen N; Motosugi U; Morisaka H; Ichikawa S; Sano K; Ichikawa T; Matsuda M; Fujii H; Onishi H
    Magn Reson Med Sci; 2016; 15(1):49-59. PubMed ID: 26104079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm.
    Becker AS; Barth BK; Marquez PH; Donati OF; Ulbrich EJ; Karlo C; Reiner CS; Fischer MA
    Eur J Radiol; 2017 Jan; 86():33-40. PubMed ID: 28027763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid-enhanced MR Imaging and Dynamic CT.
    Choi SH; Lee SS; Kim SY; Park SH; Park SH; Kim KM; Hong SM; Yu E; Lee MG
    Radiology; 2017 Mar; 282(3):771-781. PubMed ID: 27797675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
    Santillan C; Fowler K; Kono Y; Chernyak V
    Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced high temporal-resolution hepatic arterial-phase imaging with view-sharing technique: Impact on the LI-RADS category.
    Goshima S; Noda Y; Kajita K; Kawai N; Koyasu H; Kawada H; Matsuo M; Bae KT
    Eur J Radiol; 2017 Sep; 94():167-173. PubMed ID: 28709718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
    Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
    J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of gadoxetic acid-enhanced MR for small hypervascular hepatocellular carcinoma and the concordance rate of Liver Imaging Reporting and Data System (LI-RADS).
    Bae JS; Kim JH; Yu MH; Lee DH; Kim HC; Chung JW; Han JK
    PLoS One; 2017; 12(5):e0178495. PubMed ID: 28558068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study.
    Fowler KJ; Tang A; Santillan C; Bhargavan-Chatfield M; Heiken J; Jha RC; Weinreb J; Hussain H; Mitchell DG; Bashir MR; Costa EAC; Cunha GM; Coombs L; Wolfson T; Gamst AC; Brancatelli G; Yeh B; Sirlin CB
    Radiology; 2018 Jan; 286(1):173-185. PubMed ID: 29091751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Imaging Reporting and Data System:: Substantial Discordance Between CT and MR for Imaging Classification of Hepatic Nodules.
    Zhang YD; Zhu FP; Xu X; Wang Q; Wu CJ; Liu XS; Shi HB
    Acad Radiol; 2016 Mar; 23(3):344-52. PubMed ID: 26777590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.